Navigation Links
Study finds 'rescue course' of antenatal steroids improves outcome in premature babies
Date:1/29/2009

WASHINGTON, DC In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, researchers will unveil findings that show that premature babies born before 34 weeks have a 31 percent reduction in serious complications when given a "rescue course" of Antenatal Corticosteroids (ACS) steroids with no adverse side effects noted.

"Premature babies are very susceptible to respiratory problems which may lead to additional severe complications," said Dr. James Kurtzman, M.D. (Associate Professor, UC Irvine Medical Center). "Antenatal steroids clearly reduce the risk of these respiratory complications."

Years ago doctors gave multiple courses of antenatal steroids to mothers who were at risk for delivering prematurely. However, certain studies found that there were possible adverse affects to multiple ACS courses because babies were found to have slightly smaller head circumferences and lower birth weights. As a result the National Institutes of Health (NIH) recommended further study.

"The effect (of the NIH recommendation) was that doctors were only giving one ACS course, and they were nervous about when to give it for the best effect. They often waited until the last minute, and some women didn't get a complete treatment or didn't get it at all," said Dr. Kurtzman. "What this study has found is that we can give women who threaten to deliver prematurely an initial ACS course, and if they remain pregnant, we can give one 'rescue course' closer to delivery. By doing so, the babies' complications are reduced by about a third with no adverse side effects found."

In this study, which took place over five years in 18 different medical centers and was supported by the Pediatrix Medical Group, 437 patients were randomized (233 in the study group, and 214 in the placebo group). The results showed a significant reduction in composite neonatal morbidity for babies born prior to 34 weeks in the "rescu
'/>"/>

Contact: Vicki Bendure
vicki@bendurepr.com
202-374-9259
Society for Maternal-Fetal Medicine
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Brain structure assists in immune response, according to Penn vet study
2. Study finds MRSA in Midwestern swine, workers
3. New study provides further evidence that apple juice can delay onset of Alzheimers disease
4. UD research study to shed light on emerging seaborne pathogen
5. Study links water pollution with declining male fertility
6. UGA study may give hope that ivory-billed woodpeckers still around
7. Evolutionary process more detailed than previously believed, study shows
8. Researchers to use K-States BSL-3 Lab for $1 million study of fungus threatening wheat crops
9. Human beta cells can be easily induced to replicate, according to study in Diabetes
10. Primate culture is just a stones throw away from human evolution, study finds
11. Disabling enzyme allows mice to gorge without becoming obese, new study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2012)... Athens, Ga. The rate at which the rabies ... ecological traits of its hosts, according to researchers at ... Control and Prevention and Katholieke Universiteit Leuven in Belgium. ... PLoS Pathogens , found that the host,s geographical location ... of evolution. Rabies viruses in tropical and sub-tropical bat ...
(Date:5/18/2012)... everyday life, we use gasoline, diesel, plastics, rubbers, ... oil through petrochemical refinery processes. However, this is ... fossil resources. Furthermore, our world is facing problems ... due to the increasing use of fossil resources. ... use of renewable non-food biomass for the production ...
(Date:5/18/2012)... the winners of their 6th Annual Research Awards ... the very best research that has been made ... guests attended the prestigious ceremony including leading researchers, ... world. , The winners were selected by ... journals which published more than 18,000 peer-reviewed open ...
Breaking Biology News(10 mins):Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 3Production of chemicals without petroleum 2BioMed Central announces winners of 6th Annual Research Awards 2Pharmacists Offer Guidance on Top Over The Counter Medications 16616 1Pharmacists Offer Guidance on Top Over The Counter Medications 16616 2Pharmacists Offer Guidance on Top Over The Counter Medications 16616 3Researchers report widespread use of medications among pregnant women 81301 1Researchers report widespread use of medications among pregnant women 81301 2Rice born detector finds heaviest antimatter 18956 1Rice born detector finds heaviest antimatter 18956 2Rice born detector finds heaviest antimatter 18956 3
... Metabolic syndrome, a collection of related abnormalities like ... a major risk for developing heart disease and ... cholesterol (familial hyperlipidemia or FH) can be especially ... found that blocking the enzyme stearoyl-CoA desaturase-1 (SCD1), ...
... bioengineer Jennifer West is being recognized today with one ... O,Donnell Award from The Academy of Medicine, Engineering and ... for excellence in medical, scientific and engineering research, include ... West, a pioneer in the field of biomaterials engineering, ...
... the Stanford University Program in Biodesign have released ... requirements of medical device regulation in the United ... 2007 issue of the Journal of Medical Devices, ... versus pharmaceuticals and underscores the complexity of the ...
Other Biology News:Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3Stanford researchers publish review of US medical device regulation 2Stanford researchers publish review of US medical device regulation 3
(Date:5/16/2012)... Calif., May 16, 2012  Questcor Pharmaceuticals, Inc. ... its Board of Directors has increased the Company,s ... 5 million shares. Since the beginning ... to shareholders through the repurchase of approximately 19.2 ... of its shares as of the commencement of ...
(Date:5/15/2012)... Journal of Visualized Experiments ) will publish two articles ... Reduction Agency (DTRA). JoVE is proud ... Schafmeister and State University of New York Buffalo,s Dr. ... support of scientists conducting research for DTRA has significant ... defense threats. DTRA exists to safeguard America and its ...
(Date:5/15/2012)... May 15, 2012  OrbusNeich today announced that 12-month ... and safety outcomes involving the use of the company,s ... ® Liberte ® paclitaxel-eluting stent. The data ... I at the Lukaskrankenhaus in Neuss, Germany, at EuroPCR ... set, the clinically driven target lesion failure (TLF) rate ...
(Date:5/15/2012)... Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation ... trials, is pleased to announce today that the expertise ... subsidiary, Antigen Express, Inc., has been expanded by the ... research and immuno-therapeutic treatments of breast cancer: ... University School of Medicine Melvin and Bren ...
Breaking Biology Technology:Questcor Pharmaceuticals Expands Repurchase Program 2Questcor Pharmaceuticals Expands Repurchase Program 3Questcor Pharmaceuticals Expands Repurchase Program 4Questcor Pharmaceuticals Expands Repurchase Program 5JoVE partners with US government to publish cutting-edge defense research 2OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 2OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 3OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 4Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 2Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 3Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 4
... 8 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... the leading plasma-based pharmaceutical companies,in the People,s Republic ... present at the upcoming SIG Second Annual Beijing ... the Grand Hyatt Beijing Hotel in Beijing., ...
... 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus ... Copegus(R) -, - Safety and ... ... Inc.,(Nasdaq: VRUS ) announces the preliminary results of the fourth cohort of a,4-week Phase ...
... and DUBLIN, Ireland, Sept. 8 /PRNewswire-FirstCall/,-- Concuity, ... TTPA ) and a leading,provider of contract ... HFMA") and services, today announced that Valley ... Compliance suite to more,accurately calculate payments from ...
Other Biology Technology:China Biologic Products to Present at the SIG Beijing Management Summit 2China Biologic Products to Present at the SIG Beijing Management Summit 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 2Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 3Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 4